Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition

Weight Loss drug maker Eli Lilly And Co (NYSE:LLY) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Verve’s lead program (VERVE-102) is a potential first-in-class in vivo gene…

This story appeared on benzinga.com, 2025-06-17 12:07:25.
The Entire Business World on a Single Page. Free to Use →